BridgeMD
New treatment option for Recurrent Acute Pancreatitis
Official title Evaluation of Pirfenidone as a Novel Therapeutic Strategy Against Recurrent Acute Pancreatitis.
ClinicalTrials.gov ID: NCT06253117
What this study is testing
What is Pirfenidone?
Pirfenidone is an investigational medicine, being studied as a potential treatment for recurrent acute pancreatitis.
Plain-language explanation of the investigational treatment - it is being studied and is not an approved or proven therapy. The study team can confirm the details.
- What it's testing
- This clinical will evaluate the safety, tolerability and early efficacy of pirenidone in patients with recurrent acute pancreatitis.
- Phase 2: a mid-size study of how well it works
- Time commitment: about 8 years
- You might receive a placebo (an inactive treatment) instead of the study drug, decided by chance. You may not know which one you got.
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 to 85
You may be able to join if
- Patients 18 - 85 years of age
- Two or more documented attacks of acute pancreatitis, separated by 3 months from one another, defined by at least 2 of the following 3:
- amylase or lipase values, or both, that are greater than 3 times the upper limit of normal values
- characteristic cross-sectional imaging
- typical upper abdominal pain according to the revised Atlanta classification28
You likely can't join if
- Age \ 85 years.
- Body weight \> 200 kg.
- Ongoing AP (in right clinical situation defined by pain\>3, vomiting ≥once a week, fever or chills, not tolerating light diet) or diagnosis of AP in...
- Diagnosis of chronic pancreatitis, one of the following
- Ductal stricture, calcification and/or atrophy, as seen on CT scan/MRI
- 5 or more of the 9 EUS criteria used to diagnose CP
See the full eligibility criteria
- Patients 18 - 85 years of age
- Two or more documented attacks of acute pancreatitis, separated by 3 months from one another, defined by at least 2 of the following 3:
- amylase or lipase values, or both, that are greater than 3 times the upper limit of normal values
- characteristic cross-sectional imaging
- typical upper abdominal pain according to the revised Atlanta classification28
- Drug/placebo treatment to start
- Mild AP Patient is discharged out of the hospital 30 days after diagnosis of mild AP
- Moderate Severe or Severe AP Patient is discharged out of hospital Intra-abdominal collections are either resolved on imaging, or are improving and asymptomatic (VAS Pain score ≤3 [with or without pain medication]...
- Ability to understand and the willingness to sign a written informed consent document and medical release
- Willing and able to comply with trial protocol and follow up
- 2nd AP episode despite correction of the AP etiology (if identified) after the 1st episode as follows i. Patients with biliary pancreatitis who have undergone cholecystectomy, with or without ERCP (if indicated) ii...
- Age \ 85 years.
- Body weight \> 200 kg.
- Ongoing AP (in right clinical situation defined by pain\>3, vomiting ≥once a week, fever or chills, not tolerating light diet) or diagnosis of AP in previous 30 days.
- Diagnosis of chronic pancreatitis, one of the following
- Ductal stricture, calcification and/or atrophy, as seen on CT scan/MRI
- 5 or more of the 9 EUS criteria used to diagnose CP
- Known hypersensitivity to Pirfenidone.
- AST/ALT \> 3 times the upper normal limit.
- Alkaline phosphatase \>2.5 times the upper normal limit.
- Bilirubin higher than upper normal limit.
- Moderate to severe heart failure and/or coronary heart disease (New York Heart Association (NYHA) Functional Class III/IV).
- On home oxygen or home mechanical ventilation.
- Advanced liver disease as defined by Child-Pugh cirrhosis B or C.
- Paralytic ileus or significant nausea and vomiting preventing administration of light diet.
- Chronic diarrhea (\>6 months, 3 or more stools/day-Clinically not appearing to be steatorrhea [fecal fat if done less than 15 g per day and fecal elastase if done more than 100].Active cancer (on chemotherapy, radiation...
- Known cancer that is end-stage with ongoing palliative care or for which palliative care is appropriate.
- Known history of infective hepatitis (Hepatitis B or C)[can enroll if treatment and cure is documented]
- Ongoing photosensitivity and rash.
- Known live vaccines or therapeutic infectious agents within one month of admission.
- Known pregnancy or lactation at the time of admission.
- Women of childbearing potential who are not on oral or injectable contraceptives or IUDs, and do not consent to adequate contraception while on, and for 90 days after the administration of the drug/placebo.
- Known to be currently participating in a trial testing any investigational medicinal product or participation in a clinical study involving a medicinal product in the last three months.
- Problematic pattern of alcohol use or moderate to severe alcohol use disorder (Appendix 2)
- Substance use disorder (except recreational or medicinal use of marijuana) [if patient underwent and completed a rehab program, has not used substances for at least one year, and has an adequate support system, they may...
- Family or personal history of long QT syndrome (\> 500 msec).
- Strong CYP1A2 inhibitors (e.g., fluvoxamine, enoxacin) or moderate CYP1A2 Inhibitors (e.g., ciprofloxacin).
- Renal disease with GFR \< 30.
- Any condition other than above that, in the opinion of the investigator, is likely to result in the death of the patient within the next 2 years.
- Any condition that, in the opinion of the investigator, might be significantly exacerbated by the known side effects associated with the administration of Pirfenidone.
The study team makes the final eligibility decision.
Where it's taking place
- Birmingham, Alabama, United States
- Rochester, Minnesota, United States
Compensation & support
Compensation mentioned.
ClinicalTrials.gov doesn't provide a reliable structured field for payment or travel support - confirm details with the study team.
Questions & answers
Do participants get paid in this trial?
This study's listing includes signals that participants may be compensated or receive a stipend. Amounts vary and are set by the study team - confirm the details with them.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The study runs about 8 years per participant, based on its public description. The team confirms the exact schedule and number of visits before you enroll.
Who can join this trial?
This study is enrolling all sexes, 18 years to 85 years. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Birmingham, Alabama, United States; Rochester, Minnesota, United States. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.